AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Prompt Security raises $18 million Series A to protect enterprises from GenAI risks
More news

UroGen

5 stories about UroGen
אריה בלדגרין דוקטור מנכ"ל ו ממייסדי קייט פארמה

”Exits are not a Strategy. I Never put up a ‘For Sale’ Sign”

23.05.20|Sophie Shulman and Golan Hazani
Arie Belldegrun, chairman of UroGen Pharma, talks about catching Covid-19 and gaining FDA approval in the midst of a global pandemic
נאסדק

Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

24.04.19|CTech
The two companies will collaborate on the research of a “therapeutic area of mutual interest”
נאסדק

Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq

24.01.19|Lilach Baumer
Goldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering
רון בנצור

Sustained Drug Release Company UroGen Submits New Drug Application to FDA

12.07.18|Amir Rosenbaum
Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections
default image

Allergan Partners with Urine Incontinence Treatment Company

08.11.17|Lilach Baumer
Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen